StudyFinder
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Recruiting
This study will evaluate the clinical activity/efficacy of MRTX849 in cohorts of patients having selected solid tumor malignancies with KRAS G12C mutation.
All
18 Years and over
Inclusion Criteria:
• Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
• Unresectable or metastatic disease
• Standard treatment is not available or patient declines; first-line treatment for NSCLC for certain cohorts
• Adequate organ function
Exclusion Criteria:
• History of intestinal disease or major gastric surgery or inability to swallow oral medications
• Other active cancer
Drug: MRTX849, Drug: Pembrolizumab, Drug: Cetuximab, Drug: Afatinib
Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
KRAS, NSCLC, Colorectal Cancer, Colon Cancer, Metastatic Cancer, Pancreatic Cancer, Adagrasib, STK11 mutation, KRAS G12C, Clinics and Surgery Center (CSC), Phase I Clinic
Manish Patel - patel069@umn.edu
Amit Kulkarni
Phase 1/Phase 2
STUDY00009695
NCT03785249
See this study on ClinicalTrials.gov